Screener
ANI Pharmaceuticals ANIP Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $266.04M+25.9% | $237.46M+20.5% | $247.06M+29.6% | $227.81M+53.6% | $211.37M+53.1% | ||
| $100.16M+34.2% | $93.58M+28.1% | $100.27M+24.9% | $93.39M+48.1% | $74.62M+29.3% | ||
| $165.89M+21.3% | $143.88M+16.0% | $146.79M+33.1% | $134.42M+57.7% | $136.76M+70.2% | ||
| 62.4%-2.3pp | 60.6%-2.4pp | 59.4%+1.5pp | 59%+1.5pp | 64.7%+6.5pp | ||
| $14.75M-10.8% | $10.6M+0.3% | $12.26M-26.3% | $12.3M+21.5% | $16.54M+127% | ||
| $91.66M+12.1% | $73.66M-3.8% | $82.79M+18.7% | $76.66M-3.1% | $81.77M+54.8% | ||
| $225.58M+14.2% | $198.57M+16.2% | $212.29M+8.9% | $191.57M+13.5% | $197.48M+48.6% | ||
| $40.46M+191% | $38.89M+48.5% | $34.77M— | $36.24M+277% | $13.89M+169% | ||
| 15.2%+8.6pp | 16.4%+3.1pp | 14.1%— | 15.9%+29.7pp | 6.6%+2.8pp | ||
| -$3.64M+33.1% | -$3.77M+31.3% | -$4.41M+26.7% | -$4.73M-103% | -$5.44M-16.8% | ||
| -$468K-127% | -$651K-429% | $850K+162% | -$853K+66.4% | $1.74M+2,076% | ||
| $37.1M+252% | $40.22M+101% | $31.48M+329% | $33.8M+207% | $10.53M+560% | ||
| $12.39M+527% | $10.73M+149% | $3.99M+214% | $7.18M+198% | $1.98M— | ||
| $24.71M+189% | $29.49M+88.1% | $27.49M+368% | $26.62M+210% | $8.55M+474% | ||
| 9.3%+5.2pp | 12.4%+4.5pp | 11.1%+16.5pp | 11.7%+28.0pp | 4%+5.7pp | ||
| $1.05+192% | $1.28+85.5% | $1.17+313% | $1.13+189% | $0.36+357% | ||
| $60.1M+61.7% | $59.81M+21.8% | $57.38M+1,933% | $58.87M+1,334% | $37.17M+87.1% | ||
| 22.6%+5.0pp | 25.2%+0.3pp | 23.2%+21.7pp | 25.8%+29.1pp | 17.6%+3.2pp | ||
| $40.46M+191% | $38.89M+48.5% | $34.77M+276% | $36.24M+277% | $13.89M+169% |
FAQ
- What is ANI Pharmaceuticals's revenue?
- ANI Pharmaceuticals (ANIP) generated $978.4M in revenue over the trailing twelve months, up 30.9% year over year.
- Is ANI Pharmaceuticals profitable?
- ANI Pharmaceuticals reported $108.3M in net income over the trailing twelve months, a 11.1% net margin.
- What are ANI Pharmaceuticals's profit margins?
- Gross margin is 60.4% and operating margin is 15.4%, with a 11.1% net margin.
- What is ANI Pharmaceuticals's earnings per share?
- ANI Pharmaceuticals's diluted EPS over the trailing twelve months is $4.63.
- Where does ANI Pharmaceuticals's income statement data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
